Phase III
ObsEva Sa highlighted a data point from a late-stage trial that showed its fertility treatment nolasiban was successful in improving the pregnancy rate of some women following in vitro fertilization.
Eli Lilly and Company published results from a new Phase IIIb clinical trial of Trulicity (dulaglutide) in combination with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, which has shown improved blood sugar control in adults with type 2 diabetes.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) offered a negative opinion on Puma Biotechnology’s application for neratinib for breast cancer.
The U.S. Food and Drug Administration (FDA) has granted Shire’s Biologics License Application (BLA) for lanadelumab (SHP643) priority review.
Vertex Pharmaceuticals announced it is starting its first Phase III trial of VX-659, a triple combination of the VX-659, tezacaftor and ivacaftor for cystic fibrosis.
In an already competitive diabetes market, Novo Nordisk may have gained a significant edge with the results of its Phase III trial of GLP-1 drug oral semaglutide.
AbbVie and Neurocrine Biosciences’ Phase III ELARIS UF-1 clinical trial of elagolix for uterine fibroids hit its primary endpoint.
Aimmune Therapeutics announced late-stage trial results that showed its peanut allergy therapy was effective in more than 67 percent of juvenile patients.
Vertex has declined to comment, but BioCentury received a copy of the letter the company sent to laboratories explaining.
Detailed results from the JAVELIN Lung 200 trial will be submitted for presentation at an upcoming medical congress.
PRESS RELEASES